

FEB 26 2001
TECH CENTER 1600/3300

1647
RECEIVED
MAR 05 2001

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-LJ 3430	
SERIAL NO: 09/228,866	FILING DATE: January 12, 1999	EXAMINER: S. Turner	GROUP ART UNIT: 1647	
INVENTION: MOLECULES THAT HOME TO A SELECTED ORGAN IN VIVO				

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on February 22, 2001.

By: Andrea L. Gashler
Andrea L. Gashler, Reg. No.: 41,029

February 22, 2001
Date of Signature

Transmitted herewith is Response to Office Action mailed November 20, 2000, in connection with the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☒ Petition for a One Month Extension of Time is enclosed (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	29	-	29	-	0	x	\$9	\$18	=	\$0	\$
INDEPENDENT CLAIMS	15	-	15	-	0	x	\$39	\$78	=	\$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			<input type="checkbox"/> YES		<input checked="" type="checkbox"/> NO		\$130	\$260	=	\$0	\$
							TOTAL ADDITIONAL FEE			\$0	\$

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

☒ A check in the amount of \$55.00 is enclosed, \$55.00 of which covers the small entity fee for the one-month extension of time.


Inventors: Ruoslahti and Pasqualini
Serial No.: 09/228,866
Filed: January 12, 1999
Page 2 of 2

- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 C.F.R. 1.17.
- ☒ The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

February 22, 2001
Date

Andrea L. Gashler
Andrea L. Gashler
Registration No. 41,029
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-LJ 3430

Amend
16/12
Linda
3/19/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Ruoslahti and Pasqualini)

Serial No: 09/228,866)

Filed: January 12, 1999)

For: MOLECULES THAT HOME TO A)
SELECTED ORGAN IN VIVO)

Commissioner for Patents
Washington, D.C. 20231

Group Art Unit: 1647

Examiner: S. Turner

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Washington, D.C., 20231, on
February 22, 2001.

By *Andrea L. Gashler*
Andrea L. Gashler, Reg. No. 41,029

February 22, 2001
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed
November 20, 2000, entry of the following amendments and
consideration of the following remarks respectfully is requested.

AMENDMENTS

Please amend the following claims:

Sub E1
14. (Twice Amended) An isolated [A] peptide that
selectively homes to brain, consisting of the amino acid
sequence:

D'
X₁SRLX₂ (SEQ ID NO: 45),

wherein X₁ and X₂ each is 1 to 10 independently
selected amino acids

and wherein said peptide exhibits at least two-fold
greater specific binding to brain than to kidney.